SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

puzzle brain vector ILLUSTRATION ICON
Alzheimer’s disease
FDA Clears First Alzheimer’s Blood Test, Lending ‘Momentum’ to Lilly’s Kisunla, Biogen’s Leqembi
Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s disease therapies.
May 19, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration of two arrows merging into one
Mergers & acquisitions
BioMarin Expands Enzyme Expertise With $270M Inozyme Buy
The star of the acquisition is the enzyme replacement therapy INZ-701, being developed for the rare disease ENPP1 deficiency.
May 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Incyte's logo on its building in Delaware
Approvals
Incyte’s PD-1 Blocker Wins First-Line Anal Cancer Approval
The FDA also approved the use of Zynyz as a monotherapy for patients with squamous cell carcinoma of the anal canal who are intolerant to platinum chemotherapy or whose disease has progressed.
May 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Sarepta Therapeutics
Duchenne muscular dystrophy
Sarepta Seeks to Strengthen Elevidys’ Case With Data in Older Kids
Since Elevidys’ accelerated approval in 2023, experts have been clamoring for more data, particularly in older and non-ambulatory children. New results, presented Friday, show mobility improvements in 8- to 9-year-old patients after one year of follow-up.
May 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Vector of a woman holds her hand near ear and listens carefully isolated on blue background
RNA editing
Lilly Makes $1.3B RNA Editing Bet With Rznomics to Build Out Hearing Loss Pipeline
Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.
May 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Life is full of challenges and unexpected obstacles. Use these experiences as motivation to keep pushing forward and striving for your goals
Neurodegenerative disease
FDA Delays Decision Date on Biohaven’s Spinocerebellar Ataxia Application
The FDA also changed its tune and is now planning to convene an advisory committee to discuss Biohaven’s application.
May 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Government
RFK Jr. Firm on HHS Cuts, Wobbles on Measles Vaccine
At a sometimes-contentious U.S. Senate hearing, the Health and Human Services secretary was evasive on the rationale behind cuts being made to the department and his endorsement of the measles vaccine amid a rapidly growing outbreak.
May 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Gentilly, France, March 21, 2021: Exterior view of the Sanofi headquarters building. Sanofi is a French multinational company specializing in the health sector
Manufacturing
Sanofi Hops Aboard US Manufacturing Blitz With $20B Commitment
Sanofi expects to add “a significant number of high-paying jobs” in the U.S. with $20 billion investment through 2030.
May 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Lungs health and pulmonology as a respiratory medicine conept for pulmonary science and lung cancer or respiration disease and bronchi breathing or asthma symbol in a 3D illustration style.
Lung Cancer
AbbVie’s ADC Nabs Accelerated Approval for Lung Cancer
AbbVie’s Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who have received prior lines of treatment.
May 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Art 3d banner collage of business people dollar roll cooperation success payment capital profit transaction money corruption.
MASH
GSK Buys Phase III–Ready Liver Drug in Potential $2B Deal To Play in MASH Arena
GSK secures rights to Boston Pharmaceuticals’ efimosfermin alfa, which the pharma plans to develop for fatty liver diseases such as metabolic dysfunction-associated steatohepatitis and alcohol-related liver disease.
May 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Crumpled paper balls fly into a miniature bucket, the concept of searching for new ideas
Lung cancer
GSK, iTeos Abandon TIGIT Therapy, Adding to Long List of Recent Class Failures
Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck squamous cell carcinoma.
May 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Businessman team walking at a crossroads following the arrows
Arcturus Prunes Early-Stage Pipeline, Leans Into mRNA Therapies
Arcturus is extending its cash runway into 2028 by discontinuing its early-stage vaccine candidates.
May 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Pleasanton, CA, USA - Feb 21, 2024: Exterior view of the headquarters of Roche Molecular Diagnostics (RMD) in Pleasanton, California. F. Hoffmann-La Roche AG is a Swiss pharmaceutical company.
Manufacturing
Roche Continues US Investments With $550M Diagnostics Push in Lilly’s Backyard
Roche envisions its Indianapolis site as a “major hub” for the manufacturing of its continuous glucose monitoring systems. The news comes on the heels of an announced $700 million investment in North Carolina.
May 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Bayer office in Basel, Switzerland
Earnings
Bayer’s Continued Restructuring Claims 2,000 Jobs and Thins Management Layers
Meanwhile, Bayer CEO Bill Anderson said Donald Trump’s Most Favored Nations policy could present an opportunity for European countries to make sure they are also funding their “fair share” of biopharma innovation.
May 13, 2025
 · 
3 min read
 · 
Tristan Manalac
Roche's signage at its office in France
Manufacturing
Roche’s Genentech Earmarks $700M for North Carolina Plant as Billion-Dollar US Pledge Hangs in Balance
The commitment is part of Roche’s recently announced $50 billion investment in the U.S., but a company spokesperson said that could change if certain yet-unspecified policies are implemented that could “harm our industry’s ability to operate and innovate in America.”
May 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More